- Home
- ABUS vs PRSU Comparison
ABUS vs PRSU Comparison
Compare ABUS & PRSU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- PRSU
- Stock Information
- Founded
- ABUS 2005
- PRSU 1926
- Country
- ABUS United States
- PRSU United States
- Employees
- ABUS N/A
- PRSU N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- PRSU Business Services
- Sector
- ABUS Health Care
- PRSU Consumer Discretionary
- Exchange
- ABUS Nasdaq
- PRSU Nasdaq
- Market Cap
- ABUS 906.7M
- PRSU 959.1M
- IPO Year
- ABUS N/A
- PRSU N/A
- Fundamental
- Price
- ABUS $4.57
- PRSU $32.41
- Analyst Decision
- ABUS Strong Buy
- PRSU Strong Buy
- Analyst Count
- ABUS 2
- PRSU 3
- Target Price
- ABUS $5.00
- PRSU $31.33
- AVG Volume (30 Days)
- ABUS 932.9K
- PRSU 186.8K
- Earning Date
- ABUS 11-13-2025
- PRSU 11-05-2025
- Dividend Yield
- ABUS N/A
- PRSU N/A
- EPS Growth
- ABUS N/A
- PRSU 902.95
- EPS
- ABUS N/A
- PRSU 10.75
- Revenue
- ABUS $14,606,000.00
- PRSU $441,143,000.00
- Revenue This Year
- ABUS $138.02
- PRSU $22.00
- Revenue Next Year
- ABUS N/A
- PRSU $8.35
- P/E Ratio
- ABUS N/A
- PRSU $3.21
- Revenue Growth
- ABUS 116.64
- PRSU 4.63
- 52 Week Low
- ABUS $2.71
- PRSU $26.66
- 52 Week High
- ABUS $5.10
- PRSU $46.66
- Technical
- Relative Strength Index (RSI)
- ABUS 51.26
- PRSU 38.58
- Support Level
- ABUS $4.41
- PRSU $32.20
- Resistance Level
- ABUS $4.87
- PRSU $34.85
- Average True Range (ATR)
- ABUS 0.24
- PRSU 1.45
- MACD
- ABUS -0.01
- PRSU -0.20
- Stochastic Oscillator
- ABUS 40.91
- PRSU 6.07
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About PRSU Pursuit Attractions and Hospitality Inc. Common Stock
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, and Iceland. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.